<DOC>
	<DOC>NCT00211809</DOC>
	<brief_summary>The research project is a controlled pilot study of the efficacy of cognitive-behavioral therapy (CBT) as an adjunct to serotonin reuptake inhibitor (SRI) pharmacotherapy in body dysmorphic disorder (BDD). This study assesses the efficacy of CBT in comparison to relaxation and stress management training (RSMT), an active control treatment</brief_summary>
	<brief_title>CBT as an Adjunct to SRIs in the Treatment of BDD</brief_title>
	<detailed_description>In total, 20 BDD patients aged 16 through 65 will participate. To be eligible they must meet DSM-IV criteria for BDD, have a score of 20 or greater on the BDD modification of the Yale Brown Obsessive-Compulsive Scale (BDD-YBOCS) and be on a stable, therapeutic does of an SRI (at least 12 weeks on the SRI with 8 weeks at a therapeutic dose: acceptable medications (therapeutic daily doses) are citalopram (40mg), clomipramine (150mg), fluoxetine (40mg), fluvoxamine (150mg), paroxetine (40mg), sertraline (50mg), and venlafaxine (150mg).</detailed_description>
	<mesh_term>Body Dysmorphic Disorders</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Age 1665 A diagnosis of DSMIV BDD or its delusional variant (delusional disorder, somatic type) Ability to communicate meaningfully with the investigators Competent to provide written consent, if over 18 years old, or competent to provide written assent, if 1617 years, 11 months Parental consent, if under 18 years old For phase two: must be on a stable therapeutic dose of one of the following SRI medications for at least 8 weeks: fluoxetine, fluvoxamine, venlafaxine, clomipramine, paroxetine, citalopram, or sertraline. current or lifetime diagnosis of any DSM_IV psychotic disorder not attributable to delusional BDD, current or lifetime diagnosis of DSMIV bipolar disorder, current or recent (within 2 months of study entry) DSMIV alcohol or substance dependence or abuse, recent suicide attempt, or suicidal ideation that warrants consideration of hospitalization, need for inpatient or partial hospital treatment, use of any medication prescribed for the treatment of BDD other than SRIs, including tricyclic antidepressants, buspirone, or neuroleptics, presence of any significant and/or unstable medical condition, females who are pregnant or breastfeeding, or who are sexually active and not using adequate contraception.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Body Dysmorphic Disorder</keyword>
	<keyword>SRIs</keyword>
	<keyword>Cognitive Behavioral Therapy</keyword>
</DOC>